BR112015021495A2 - fabricação contínua integrada de substâncias de droga de proteína terapêutica - Google Patents

fabricação contínua integrada de substâncias de droga de proteína terapêutica

Info

Publication number
BR112015021495A2
BR112015021495A2 BR112015021495A BR112015021495A BR112015021495A2 BR 112015021495 A2 BR112015021495 A2 BR 112015021495A2 BR 112015021495 A BR112015021495 A BR 112015021495A BR 112015021495 A BR112015021495 A BR 112015021495A BR 112015021495 A2 BR112015021495 A2 BR 112015021495A2
Authority
BR
Brazil
Prior art keywords
therapeutic protein
protein drug
drug substances
continuous manufacturing
integrated continuous
Prior art date
Application number
BR112015021495A
Other languages
English (en)
Inventor
Konstantinov Konstantin
Godawat Rahul
Jain Sujit
Warikoo Veena
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112015021495A2 publication Critical patent/BR112015021495A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1807—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using counter-currents, e.g. fluidised beds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size selective separation, e.g. size exclusion chromatography, gel filtration, permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3814—Affinity chromatography of the substrate or co-factor - enzyme type
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/422—Displacement mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/52—Mobile; Means for transporting the apparatus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/10—Separation or concentration of fermentation products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Abstract

resumo patente de invenção: "fabricação contínua integrada de substâncias de droga de proteína terapêutica". a presente invenção refere-se a processos de biofabricação contínuos integrados para a produção de uma substância de droga de proteína terapêutica. são também proporcionados sistemas que são capazes de produzir continuamente uma substância de droga de proteína terapêutica.
BR112015021495A 2013-03-08 2014-03-03 fabricação contínua integrada de substâncias de droga de proteína terapêutica BR112015021495A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775060P 2013-03-08 2013-03-08
US201361856390P 2013-07-19 2013-07-19
PCT/US2014/019909 WO2014137903A2 (en) 2013-03-08 2014-03-03 Integrated continuous manufacturing of therapeutic protein drug substances

Publications (1)

Publication Number Publication Date
BR112015021495A2 true BR112015021495A2 (pt) 2017-07-18

Family

ID=50424717

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021495A BR112015021495A2 (pt) 2013-03-08 2014-03-03 fabricação contínua integrada de substâncias de droga de proteína terapêutica

Country Status (15)

Country Link
US (5) US9650412B2 (pt)
EP (1) EP2964663A2 (pt)
JP (2) JP6608705B2 (pt)
KR (1) KR102257356B1 (pt)
CN (1) CN105377874A (pt)
AU (3) AU2014226126B2 (pt)
BR (1) BR112015021495A2 (pt)
CA (1) CA2902854C (pt)
HK (1) HK1219964A1 (pt)
IL (2) IL274646B (pt)
MX (2) MX2015012114A (pt)
RU (2) RU2662929C2 (pt)
SG (3) SG10201709131UA (pt)
TW (3) TW202043252A (pt)
WO (1) WO2014137903A2 (pt)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
US10980244B2 (en) 2008-11-04 2021-04-20 The Quaker Oats Company Whole grain composition comprising hydrolyzed starch
US10689678B2 (en) 2008-11-04 2020-06-23 The Quaker Oats Company Method and composition comprising hydrolyzed starch
JP2014510103A (ja) 2011-03-21 2014-04-24 ペプシコ，インコーポレイテッド 高酸ｒｔｄ全粒粉飲料を調製する方法
WO2013009973A1 (en) 2011-07-12 2013-01-17 Pepsico, Inc. Method of preparing an oat-containing dairy beverage
JP6182210B2 (ja) 2012-06-29 2017-08-16 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質精製プロセス中のウイルスの不活性化方法
EP2958988A2 (en) 2013-02-22 2015-12-30 Genzyme Corporation Microcarrier perfusion culturing methods and uses thereof
SG11201506339RA (en) 2013-02-22 2015-09-29 Genzyme Corp Microcarrier perfusion culturing methods and uses thereof
RU2662929C2 (ru) 2013-03-08 2018-07-31 Джензим Корпорейшн Интегрированное непрерывное производство терапевтических белковых лекарственных веществ
TW202332774A (zh) 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
WO2015075070A1 (en) 2013-11-20 2015-05-28 Cmc Biologics A/S A bioreactor system and method for producing a biopolymer
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
EP3102935B1 (en) 2014-02-07 2021-01-27 CMC Biologics A/S A bioreactor arrangement and continuous process for producing and capturing a biopolymer
RU2710967C9 (ru) 2014-04-16 2020-08-12 Кмк Биологикс А/С Способ отъемно-доливной ферментации с высокой плотностью клеток
TWI743024B (zh) 2014-06-06 2021-10-21 美商健臻公司 灌注培養方法及其用途
TWI707949B (zh) 2014-06-09 2020-10-21 美商健臻公司 種子罐培養法（ｓｅｅｄ ｔｒａｉｎ ｐｒｏｃｅｓｓｅｓ）及其用途
RU2713126C2 (ru) * 2014-10-24 2020-02-03 Джензим Корпорейшн Способ предотвращения контаминации системы
CN107567495A (zh) 2014-12-22 2018-01-09 建新公司 培养哺乳动物细胞的方法
EP3236772A4 (en) * 2014-12-22 2018-10-17 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
JP6824555B2 (ja) * 2015-03-31 2021-02-03 サイティバ・スウェーデン・アクチボラグ 液体クロマトグラフィーシステム、装置、および方法
EP3015542A1 (de) 2015-05-07 2016-05-04 Bayer Technology Services GmbH Modulare anlage und verfahren zur kontinuierlichen, keimreduzierten produktion und/oder aufbereitung eines produktes
EP3093335A1 (de) * 2015-05-13 2016-11-16 Bayer Technology Services GmbH Prozessleitsystem zur regelung und steuerung einer modular aufgebauten anlage zur produktion von biopharmazeutischen und biologischen makromolekularen produkten
EP3037513A1 (de) * 2015-05-13 2016-06-29 Bayer Technology Services GmbH Verfahren zur kontinuierlichen elution eines produktes von chromatographiesäulen
SG11201803013YA (en) * 2015-10-26 2018-05-30 Lonza Ag A manufacturing facility for the production of biopharmaceuticals
JP6878762B2 (ja) * 2015-12-18 2021-06-02 ウシオ電機株式会社 光照射装置及び光照射方法
US11172695B2 (en) 2016-03-22 2021-11-16 The Quaker Oats Company Method, apparatus, and product providing hydrolyzed starch and fiber
US20170275662A1 (en) 2016-03-22 2017-09-28 The Quaker Oats Company Method and Apparatus for Controlled Hydrolysis
EP3604547A1 (en) * 2016-04-14 2020-02-05 Trizell Ltd. Fixed-bed bioreactor with constant-flow pump/tubing system
US11261416B2 (en) * 2016-04-14 2022-03-01 Trizell Ltd. Fixed-bed bioreactor with constant-flow pump / tubing system
US11020686B2 (en) 2016-08-16 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
RU2021119421A (ru) 2016-08-16 2021-07-13 Джензим Корпорейшн Способы обработки текучей среды, содержащей рекомбинантный терапевтический белок, и их применение
EP3504315A4 (en) 2016-08-27 2020-04-15 3D Biotek, LLC BIOREACTOR
WO2018073717A1 (en) * 2016-10-17 2018-04-26 Enzene Biosciences Limited Continuous process for reducing heterogeneity of therapeutic protein
CN109923411B (zh) 2016-10-25 2022-05-31 里珍纳龙药品有限公司 用于色谱数据分析的方法和系统
BE1024230B1 (fr) * 2016-11-08 2017-12-20 Univercells Sa Production contenue de cellules et/ou de produits cellulaires
KR102492455B1 (ko) * 2016-11-24 2023-01-27 알베오릭스 테크놀러지스 아게 세포 배양 시스템 및 방법
EP3568152A1 (en) 2017-01-10 2019-11-20 Amicus Therapeutics, Inc. Recombinant alpha-galactosidase a for treatment of fabry disease
JP7171058B2 (ja) * 2017-02-21 2022-11-15 サイティバ・スウェーデン・アクチボラグ クロマトグラフィーシステムにおけるｕｖセル光路長の適合方法
EP3381529A1 (fr) 2017-03-29 2018-10-03 EMD Millipore Corporation Installation de traitement de liquide biologique
EP3381530A1 (fr) 2017-03-29 2018-10-03 EMD Millipore Corporation Installation de traitement de liquide biologique
WO2018183972A2 (en) * 2017-04-01 2018-10-04 Massachusetts Institute Of Technology Systems and methods for using behavior data of impurities and target proteins to design downstream processes
WO2019147310A2 (en) 2017-08-31 2019-08-01 Massachusetts Institute Of Technology Filtration systems and methods for manufacturing biologically-produced products
US20200255785A1 (en) * 2017-09-15 2020-08-13 Bristol-Myers Squibb Company Online biomass capacitance monitoring during large scale production of polypeptides of interest
WO2019060837A1 (en) * 2017-09-25 2019-03-28 Enzyvant Farber Gmbh PROCESS FOR PRODUCING RECOMBINANT HUMAN ACID CERAMIDASE
CN111344558A (zh) 2017-10-06 2020-06-26 龙沙有限公司 使用拉曼光谱法自动控制细胞培养
EA202090740A1 (ru) * 2017-10-16 2020-07-07 Ридженерон Фармасьютикалз, Инк. Перфузионный биореактор и связанные с ним способы применения
CN108101981B (zh) * 2018-01-15 2019-06-04 四川远大蜀阳药业有限责任公司 一种静注免疫球蛋白的生产工艺
AU2019214519A1 (en) * 2018-02-02 2020-06-18 Aceragen, Inc. Methods for treating Farber disease
BR112020017726A2 (pt) 2018-03-02 2020-12-22 Genzyme Corporation Análise espectral multivariada e monitoramento de biofabricação
KR20200136454A (ko) * 2018-03-27 2020-12-07 브리스톨-마이어스 스큅 컴퍼니 자외선 신호를 사용한 단백질 농도의 실시간 모니터링
EP3546475A1 (en) 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
EP3773684A1 (en) * 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
US20190367858A1 (en) * 2018-06-01 2019-12-05 Lonza Ltd. Midscale Model For Organic Growth and Phasing
US10792618B2 (en) 2018-06-19 2020-10-06 Sartorius Stedim Biotech Gmbh Particle separation and/or purification of a fluid
TW202005694A (zh) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
JP7063759B2 (ja) * 2018-07-25 2022-05-09 株式会社日立プラントサービス 精製装置
EP3843869A1 (en) 2018-08-31 2021-07-07 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
CN111184636A (zh) * 2018-11-14 2020-05-22 正大天晴药业集团南京顺欣制药有限公司 含重组蛋白的药物组合物的制备
KR20210120015A (ko) * 2019-01-25 2021-10-06 엔진 바이오사이언스 리미티드 치료 단백질 생산을 위한 자동화 통합 연속 시스템 및 바이오 공정
EP3924461A2 (en) * 2019-02-15 2021-12-22 Just-Evotec Biologics, Inc. Facilities and processes to produce biotherapeutics
WO2020168315A1 (en) * 2019-02-15 2020-08-20 Just-Evotec Biologics, Inc. Automated biomanufacturing systems, facilities, and processes
EP3947627A1 (en) * 2019-04-01 2022-02-09 Boehringer Ingelheim International GmbH Integrated and continuous recombinant protein manufacturing
KR20210149117A (ko) * 2019-04-03 2021-12-08 젠자임 코포레이션 재조합 단백질의 연속 생산
GB201908612D0 (en) * 2019-06-17 2019-07-31 Ge Healthcare Bio Sciences Ab A method for separating biomolecules
CN110348089B (zh) * 2019-06-28 2021-05-04 浙江大学 基于层析模型实现多柱连续流层析设计及分析的方法
CN110348090B (zh) * 2019-06-28 2021-05-04 浙江大学 基于人工神经网络实现多柱连续流层析设计及分析的方法
FR3099066B1 (fr) * 2019-07-26 2021-08-13 Novasep Process Procédé de purification d’une substance cible avec inactivation virale
GB201911686D0 (en) * 2019-08-15 2019-10-02 Fujifilm Diosynth Biotechnologies Uk Ltd Process for purifying target substances
BR112022005211A2 (pt) 2019-09-23 2022-06-14 Genzyme Corp Medição de atributos de qualidade do produto
CA3155216A1 (en) 2019-10-22 2021-04-29 Robert Snow In-line product monitoring in integrated continuous bio-manufacturing
GB202003336D0 (en) * 2020-03-06 2020-04-22 National Institute For Bioprocesisng Res And Training A system for producing a biopharmaceutical product
EP4026892A1 (en) 2021-01-12 2022-07-13 Sartorius Stedim Biotech GmbH Device assembly and method for controlling an integrated continuous pharmaceutical or biopharmaceutical manufacturing process
GB202101775D0 (en) * 2021-02-09 2021-03-24 Cytiva Sweden Ab Method in bioprocess purification system
US20240051990A1 (en) * 2021-03-10 2024-02-15 Amgen Inc. Methods for purification of recombinant proteins
GB202109015D0 (en) * 2021-06-23 2021-08-04 Puridify Ltd A method for purifying a feed in a chromatography system
WO2023043718A1 (en) * 2021-09-14 2023-03-23 Sanofi Chromatography system
US20230202119A1 (en) * 2021-12-28 2023-06-29 Mott Corporation Selectable media filter and sparger assemblies and related methods of fabrication and use
TW202342522A (zh) 2022-03-07 2023-11-01 日商武田藥品工業股份有限公司 臨床人類ｉｇｇ產品之親和層析生產
WO2023191008A1 (ja) * 2022-03-30 2023-10-05 富士フイルム株式会社 バイオ医薬品の原薬の製造方法、バイオ医薬品の原薬の製造システム、およびバイオ医薬品の原薬
WO2023191009A1 (ja) * 2022-03-30 2023-10-05 富士フイルム株式会社 バイオ医薬品の原薬の製造方法、バイオ医薬品の原薬の製造システム、およびバイオ医薬品の原薬
DE102022208467A1 (de) 2022-06-24 2024-01-04 Bilfinger Life Science Gmbh Modulare Vorrichtung und Verfahren zur kontinuierlichen Herstellung von biotechnologischen Produkten
WO2023247798A1 (de) 2022-06-24 2023-12-28 Bilfinger Life Science Gmbh Modulare vorrichtung und verfahren zur kontinuierlichen herstellung von biotechnologischen produkten
KR20240039642A (ko) * 2022-09-19 2024-03-27 주식회사 녹십자 신규 헤파란-n-설파타아제의 정제 방법

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401108A (en) 1980-02-13 1983-08-30 Thomas Jefferson University Radioactive material loading, calibration and injection systems
JPS6075530A (ja) 1983-09-30 1985-04-27 Asahi Chem Ind Co Ltd 金属元素の新しい分離精製方法
US4559175A (en) 1984-04-19 1985-12-17 The United States Of America As Represented By The Secretary Of The Air Force Halo-substituted diphospha-s-triazines and their derivatives
US4885250A (en) 1987-03-02 1989-12-05 E. I. Du Pont De Nemours And Company Enzyme immobilization and bioaffinity separations with perfluorocarbon polymer-based supports
US5612016A (en) 1988-04-01 1997-03-18 Immunomedics, Inc. Conjugates of antibodies and bifunctional ligands
US5169936A (en) 1989-04-14 1992-12-08 Biogen, Inc. Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
EP0455757B1 (en) 1989-08-04 1999-03-31 GRANDICS, Peter An integrated cell culture-protein purification system for the automated production and purification of cell culture products
US5244816A (en) 1989-10-11 1993-09-14 Akzo N.V. Method for purifying chelator conjugated compounds
WO1992017403A1 (en) 1991-04-05 1992-10-15 Brigham Young University Support bonded polyalkylene-polyamine-poly(carboxylic acid) and extraction of metal ions therewith
RU2034853C1 (ru) 1992-07-14 1995-05-10 Научно-исследовательский институт строительных материалов при Томской государственной инженерно-строительной академии Способ получения полимерного сорбента для хроматографии
JP2871435B2 (ja) 1993-04-22 1999-03-17 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 親水性ポリマー被覆パーフルオロカーボンポリマーベースのマトリックスの製造方法
US5478924A (en) 1994-02-16 1995-12-26 Cramer; Steven M. Displacement chromatography of proteins using low molecular weight displacers
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5423982A (en) * 1994-05-31 1995-06-13 Biosepra Inc. Liquid chromatography column adapted for in situ chemical sterilization
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
US6359114B1 (en) 1995-06-07 2002-03-19 Aphton Corp. System for method for the modification and purification of proteins
AR005035A1 (es) 1995-12-11 1999-04-07 Merck Patent Ges Mit Beschränkter Haftung Procedimiento para preparar proteinas recombinantes en e. coli, mediante fermentacion con gran concentracion de celulas.
DE69739673D1 (de) 1996-11-27 2009-12-31 Genentech Inc Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix
US6955917B2 (en) 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US6265542B1 (en) 1997-10-24 2001-07-24 Genentech, Inc. Purification of molecules
CN103641885A (zh) 1998-05-06 2014-03-19 基因技术股份有限公司 用离子交换层析纯化蛋白质
DE19858892A1 (de) 1998-12-19 2000-06-21 Merck Patent Gmbh Kontinuierliches Verfahren zur Trennung von Stoffen nach Molekülgröße
GB0028879D0 (en) 2000-11-27 2001-01-10 Prometic Biosciences Ltd Adsorbents and their use
ES2370235T3 (es) 2001-02-23 2011-12-13 Immunex Corporation Recuperación eficaz de proteínas replegadas correctamente.
ITBO20010426A1 (it) * 2001-07-06 2003-01-06 Alfa Wassermann Spa Processo per la purificazione di proteine farmacologicamente attive mediante cromatografia in scambio cationico
WO2003045546A1 (en) 2001-11-27 2003-06-05 Prometic Biosciences Ltd. The use of metal-chelating adsorbents
US6660172B2 (en) 2002-01-31 2003-12-09 Koslow Technologies Corporation Precoat filtration media and methods of making and using
AU2003210802B2 (en) 2002-02-05 2009-09-10 Genentech Inc. Protein purification
US20060234226A1 (en) 2002-04-26 2006-10-19 Fahner Robert L Non-affinity purification of proteins
US6902909B2 (en) 2002-07-09 2005-06-07 Synthecon, Inc. Methods for efficient production of mammalian recombinant proteins
CA2496060C (en) 2002-09-11 2015-08-04 Genentech, Inc. Protein purification by ion exchange chromatography
NZ563078A (en) 2002-09-13 2009-07-31 Biogen Idec Inc Method of purifying polypeptides by simulated moving bed chromatography
US7157276B2 (en) 2003-06-20 2007-01-02 Biogen Idec Inc. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
AU2005217148B2 (en) 2004-02-27 2011-09-08 Octapharma Ag A method of providing a purified, virus safe antibody preparation
EP1773976B2 (en) 2004-06-04 2020-01-01 Global Life Sciences Solutions USA LLC Disposable bioreactor systems and methods
WO2006026248A1 (en) 2004-08-25 2006-03-09 Sigma-Aldrich Co. Compositions and methods employing zwitterionic detergent combinations
US9045725B2 (en) 2004-09-30 2015-06-02 Bayer Healthcare Llc Devices and methods for integrated continuous manufacturing of biological molecules
RU2389552C2 (ru) 2004-10-21 2010-05-20 Джи-И Хелткер Байо-Сайенсиз АБ Способ очистки антител
AU2005299716B2 (en) 2004-10-22 2012-09-06 Amgen Inc. Methods for refolding of recombinant antibodies
SG161210A1 (en) * 2004-12-22 2010-05-27 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
US7682510B2 (en) 2005-03-07 2010-03-23 Ge Healthcare Bio-Sciences Ab Method of sterilization
US8043833B2 (en) 2005-10-31 2011-10-25 Novo Nordisk A/S Expression of soluble therapeutic proteins
WO2007075283A2 (en) 2005-12-06 2007-07-05 Amgen Inc. Polishing steps used in multi-step protein purification processes
MX2008010604A (es) 2006-02-17 2009-03-05 Novartis Ag Purificacion y uso de pilosidades de streptococcus pneumoniae y proteinas pilosas.
US7673757B2 (en) 2006-02-17 2010-03-09 Millipore Corporation Adsorbent filter media for removal of biological contaminants in process liquids
JP2010507068A (ja) 2006-04-21 2010-03-04 バイエル・コーポレーシヨン 原位置測定のための装置、システム、方法
US20080132688A1 (en) 2006-09-22 2008-06-05 Amgen Inc. Methods for Removing Viral Contaminants During Protein Purification
WO2008073620A2 (en) * 2006-11-02 2008-06-19 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
US9597610B2 (en) 2007-03-09 2017-03-21 Ge Healthcare Bioprocess R&D Ab Packing system and method for chromatography columns
GB0704603D0 (en) 2007-03-09 2007-04-18 Ge Healthcare Bio Sciences Ab Packing system and method for chromatography columns
CN101678244B (zh) * 2007-04-17 2013-06-19 深度控股有限公司 用于连续膜吸附的方法和装置
US9109193B2 (en) 2007-07-30 2015-08-18 Ge Healthcare Bio-Sciences Corp. Continuous perfusion bioreactor system
EP3441402A1 (en) * 2007-10-30 2019-02-13 Genentech, Inc. Antibody purification by cation exchange chromatography
PT2228441E (pt) 2007-12-27 2013-08-27 Otsuka Pharma Co Ltd Enzima envolvida na síntese de equol
WO2009103791A1 (en) * 2008-02-22 2009-08-27 Genmab A/S Methods for assissing the risk of adverse events upon treatment with igg4 antibodies
EP2537862B1 (en) * 2008-06-24 2015-03-18 Octapharma AG A process of purifying coagulation factor VIII
CN102271775A (zh) 2008-12-08 2011-12-07 诺沃-诺迪斯克有限公司 多肽的逆流提纯
EP2236617A1 (en) 2009-03-31 2010-10-06 Leukocare Ag Methods of terminal sterilization of biofunctional compositions
WO2010120514A2 (en) 2009-03-31 2010-10-21 The Trustees Of The University Of Pennsylvania Antigen-binding proteins comprising recombinant protein scaffolds
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
KR101756493B1 (ko) 2009-10-29 2017-07-10 아센디스 파마 에이에스 생분해성 하이드로겔의 살균
GB0922426D0 (en) 2009-12-22 2010-02-03 Ge Healthcare Bio Sciences Ab Containers for chromatography media
US9958421B2 (en) 2009-12-22 2018-05-01 Ge Healthcare Bioprocess R&D Ab Method for dry packing chromatography columns
EP2577289B1 (en) 2010-06-03 2021-03-17 Cytiva BioProcess R&D AB A parallel assembly of chromatography column modules
US20130260419A1 (en) * 2010-12-06 2013-10-03 Thomas C. Ransohoff Continuous processing methods for biological products
CN102321316B (zh) 2011-08-25 2013-04-24 上海恒方大高分子材料科技有限公司 一种适用于γ射线辐照消毒的医用PVC材料及其制备方法
EP2656892A1 (en) 2012-04-23 2013-10-30 Merck Patent GmbH Chromatography method
EP2682168A1 (en) 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
JP6182210B2 (ja) * 2012-06-29 2017-08-16 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質精製プロセス中のウイルスの不活性化方法
SG11201502918RA (en) * 2012-10-24 2015-05-28 Genzyme Corp Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
RU2662929C2 (ru) 2013-03-08 2018-07-31 Джензим Корпорейшн Интегрированное непрерывное производство терапевтических белковых лекарственных веществ
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
EP3094391A4 (en) 2014-01-17 2017-09-20 Repligen Corporation Sterilizing chromatography columns
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途

Also Published As

Publication number Publication date
US20150183821A1 (en) 2015-07-02
WO2014137903A2 (en) 2014-09-12
IL240792A0 (en) 2015-10-29
SG10202011130TA (en) 2020-12-30
TW201518315A (zh) 2015-05-16
AU2014226126B2 (en) 2019-02-14
AU2019203128A1 (en) 2019-05-30
AU2019203128B2 (en) 2020-10-29
US9650412B2 (en) 2017-05-16
RU2015142657A (ru) 2017-04-13
RU2768003C2 (ru) 2022-03-22
CN105377874A (zh) 2016-03-02
RU2018122100A (ru) 2019-03-12
US20200317726A1 (en) 2020-10-08
IL240792B (en) 2020-05-31
SG10201709131UA (en) 2017-12-28
KR102257356B1 (ko) 2021-05-31
TW202043252A (zh) 2020-12-01
HK1219964A1 (zh) 2017-04-21
WO2014137903A3 (en) 2014-10-30
AU2021200474A1 (en) 2021-02-25
CA2902854A1 (en) 2014-09-12
AU2014226126A1 (en) 2015-10-01
US9657056B2 (en) 2017-05-23
RU2662929C2 (ru) 2018-07-31
IL274646A (en) 2020-06-30
US10711034B2 (en) 2020-07-14
US9650413B2 (en) 2017-05-16
KR20150125714A (ko) 2015-11-09
MX2020001823A (es) 2020-07-13
JP2016510981A (ja) 2016-04-14
IL274646B (en) 2022-09-01
CA2902854C (en) 2024-01-23
EP2964663A2 (en) 2016-01-13
RU2018122100A3 (pt) 2021-08-06
TWI659965B (zh) 2019-05-21
TWI702226B (zh) 2020-08-21
US20170218012A1 (en) 2017-08-03
JP2020033364A (ja) 2020-03-05
US20150232505A1 (en) 2015-08-20
JP6608705B2 (ja) 2019-11-20
MX2015012114A (es) 2016-01-12
TW201920230A (zh) 2019-06-01
SG11201506775VA (en) 2015-09-29
US20140255994A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
BR112015021495A2 (pt) fabricação contínua integrada de substâncias de droga de proteína terapêutica
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
DOP2015000185A (es) Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
ECSP15001882A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
WO2013151665A3 (en) Modified polynucleotides for the production of proteins associated with human disease
BR112015000399A2 (pt) derivados de pirazolil pirimidina
WO2013151666A3 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY35490A (es) Conjugados de fármacos con anticuerpos
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
SMT201600065B (it) Procedimento per la produzione di composti di 177lu altamente puri senza supporto nonché composti di 177lu senza supporto
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CL2015000408A1 (es) Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer.
BR112015006731A2 (pt) combinações e usos das mesmas
DOP2016000064A (es) Derivados de fenilalanina sustituidos
UY34552A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen
BR112016012002A2 (pt) Vitanolídeos úteis para o tratamento de doenças neurodegenerativas
BR112017022856A2 (pt) combinação de dose fixa inviolável que proporciona rápida liberação de duas drogas a partir de partículas
MX2016005645A (es) Composicion farmaceutica topica de acitretina.
BR112015015373A2 (pt) métodos de integração da produção de aluminoxano na produçâo de catalisador
UY35004A (es) Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]